37 completed, 20 unknown, 17 terminated, 14 recruiting. 53 Phase 2, 34 Phase 1, 5 Not applicable, 5 Phase 3, 3 Early Phase 1.
Follow Castration-resistant Prostate Cancer: new trials by email Literature Review of Castration-resistant Prostate Cancer trials Research Report on Castration-resistant Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer BL-B01D1, Abiraterone, Olaparib - Castration-resistant Prostate Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 180 | 2026-09-01 | 2026-07-23 |
| Study of Oral MRT-2359 With Apalutamide in Prostate Cancer Oral MRT-2359, Apalutamide - Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | Monte Rosa Therapeutics, Inc | 25 | 2026-08-18 | 2026-10-08 |
| Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer JANX014 - Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Janux Therapeutics | 43 | 2026-04-15 | 2026-09-03 |
| A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC 161Tb RAD402 - Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Radiopharm Theranostics, Ltd | 73 | 2026-03-05 | 2026-04-01 |
| A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types IDE034 - Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer | Phase 1 | Recruiting | IDEAYA Biosciences | 150 | 2026-02-24 | 2026-06-18 |
| Study of DCC-2812 in Participants With Advanced Genitourinary Cancers DCC-2812 - Renal Cell Carcinoma, Urothelial Carcinoma | Phase 1 | Recruiting | Deciphera Pharmaceuticals, LLC | 60 | 2025-08-27 | 2026-08-18 |
| AI Multimodal Model for Predicting CRPC Progression Risk Prostate Cancer, Castration-Resistant Prostate Cancer | Active not recruiting | Guangxi Medical University | 500 | 2025-06-01 | 2026-06-22 | |
| Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC PSMA-UCAR T (BRL-302) - Metastatic Prostate Cancer, Castration-resistant Prostate Cancer | Phase 1 | Active not recruiting | Shanghai Changzheng Hospital | 3 | 2025-03-27 | 2026-07-23 |
| GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy Investigational Agent Administration - Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Virginia Commonwealth University | 30 | 2025-02-18 | 2026-01-27 |
| 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer 177Lu-PSMA-617, Niraparib abiraterone acetate, Prednisone - Metastatic Prostate Cancer, Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Withdrawn | Baptist Health South Florida | 2024-10-01 | 2024-09-19 | |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials Prostate Cancer, Prostate Adenocarcinoma | Recruiting | Duke University | 120 | 2024-05-13 | 2025-10-15 | |
| Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer Disitamab Vedotin Injection - Castration-resistant Prostate Cancer | Phase 2 | Unknown | RemeGen Co., Ltd. | 40 | 2024-04-08 | 2024-05-23 |
| Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC Enhanced autologous PSMA-CAR T - Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer | Early Phase 1 | Active not recruiting | Shanghai Changzheng Hospital | 18 | 2024-03-03 | 2026-07-23 |
| Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study Injection, 161Tb-SibuDAB,1GBq, Injection, 177Lu-PSMA-I&T, 1GBq, Injection, 161Tb-SibuDAB, Dose Escalation - Castration-resistant Prostate Cancer | Phase 1 | Recruiting | University Hospital, Basel, Switzerland | 25 | 2024-02-20 | 2024-08-14 |
| Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) Stereotactic body radiotherapy, Adebrelimab - Prostate Cancer Metastatic, Castration-resistant Prostate Cancer | Phase 2 | Unknown | Fudan University | 30 | 2024-01-30 | 2024-02-20 |
| Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc AR Blockade, Carotuximab - Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Edwin Posadas, MD | 116 | 2023-12-27 | 2026-10-05 |
| Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer Radiotherapy, metastasectomy - Castration-resistant Prostate Cancer, Oligoprogressive | Phase 3 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 246 | 2023-12-19 | 2024-09-05 |
| Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer Olaparib, Vitamin C - Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 4 | 2023-06-30 | 2025-01-29 |
| A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects SHR3680 tablets - Castration-Resistant Prostate Cancer | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 52 | 2023-04-26 | 2023-05-15 |
Showing 20 of 103. Sign in to see all of them.
Prostatic Neoplasms (46) · Neoplasm Metastasis (11) · Carcinoma, Non-Small-Cell Lung (8) · Colorectal Neoplasms (6) · Breast Neoplasms (5) · Carcinoma, Renal Cell (5) · Triple Negative Breast Neoplasms (5) · Carcinoma, Hepatocellular (4) · Carcinoma, Transitional Cell (4) · Endometrial Neoplasms (4) · Neoplasms (4) · Neoplastic Cells, Circulating (4) · Ovarian Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Motor Activity (3)
Neoplasms (58) · Neoplasms by Site (56) · Urogenital Diseases (54) · Urogenital Neoplasms (53) · Genital Diseases (52) · Male Urogenital Diseases (52) · Genital Diseases, Male (46) · Genital Neoplasms, Male (46) · Prostatic Diseases (46) · Neoplastic Processes (14) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Neoplasms by Histologic Type (11) · Breast Diseases (10) · Neoplasms, Glandular and Epithelial (10)
enzalutamide (17) · Abiraterone Acetate (7) · abiraterone (7) · Docetaxel (6) · Prednisone (6) · pembrolizumab (5) · Radiosurgery (4) · apalutamide (4) · Blood Specimen Collection (3) · Nivolumab (3) · Radiotherapy (3) · cabozantinib (3) · radium Ra 223 dichloride (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2)
Jiangsu HengRui Medicine Co., Ltd. (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Astellas Pharma Global Development, Inc. (2) · Bayer (2) · Dana-Farber Cancer Institute (2) · Dendreon (2) · Fudan University (2) · Innocrin Pharmaceutical (2) · Institute of Cancer Research, United Kingdom (2) · Jiangnan University (2) · Modra Pharmaceuticals (2) · Novartis Pharmaceuticals (2) · Shanghai Changzheng Hospital (2) · Taro Iguchi, MD, PHD (2) · Tianjin Medical University Second Hospital (2)
United States (48) · China (14) · United Kingdom (13) · Canada (11) · France (11) · Italy (10) · Australia (8) · Belgium (8) · Spain (7) · Germany (6) · Netherlands (6) · Poland (4) · Argentina (3) · Austria (3) · Brazil (3)
Johann de Bono (2) · Adrian VS Hill (1) · Alejandro Crismatt, MD (1) · Alin Chirindel, MD (1) · Andre Bergman, MD, PhD (1) · Andrew Armstrong, MD (1) · Andrew Protheroe (1) · Anthony Joshua, MD,MBBS,PhD,FRACP (1) · Anthony M Joshua, MBBS, PhD, FRACP (1) · Arturo Delgado Herrera, MD (1) · Bruce Brown, MD (1) · Celestia S Higano, MD (1)
PMID 22894553, PMID 25104109, PMID 25123978, PMID 25171902, PMID 25361992, PMID 25917876, PMID 26278649, PMID 26854432, PMID 27091421, PMID 29272162, PMID 29590007, PMID 30126765, PMID 31082669, PMID 31428443, PMID 31564004, PMID 31830211, PMID 32203306, PMID 32448171, PMID 32926761, PMID 33744986, PMID 34077818, PMID 34197212, PMID 34491815, PMID 34518652, PMID 34845502, PMID 34965947, PMID 35101049, PMID 35643841, PMID 35690072, PMID 35731340, PMID 37058234, PMID 38167882, PMID 38204489, PMID 38425504, PMID 38924042, PMID 39151419, PMID 39361218, PMID 39965176, PMID 40906325, PMID 42031429, PMID 42117295
2017 (2), 2009 (1), 2015 (1), 2016 (1), 2023 (1), P30CA015704 (1), R01CA286127 (1), R01CA300454 (1)